Illumina, Inc.
ILMN Healthcare Diagnostics & Research
Illumina, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, down 0.66% from fiscal 2024. In the quarter to June 2026, revenue grew 9.44%, EPS fell 8.05%, free cash flow fell 18.3% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
Follow ILMN
Illumina, Inc. (ILMN) EPS (diluted)
Illumina, Inc.'s EPS (diluted) for fiscal 2025 was $5.45, compared with −$7.69 in fiscal 2024. Over the twelve months to 30 June 2026 it was $5.36. Over the past ten years it has ranged from −$28.00 (fiscal 2022) to $6.74 (fiscal 2019); the current reading is higher than 82% of that period. Illumina, Inc. ranks 10th of 52 Diagnostics & Research companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $5.45 | — |
| FY2024 | −$7.69 | — |
| FY2023 | −$7.34 | — |
| FY2022 | −$28.00 | — |
| FY2021 | $5.04 | 13.26% |
| FY2020 | $4.45 | (33.98%) |
| FY2019 | $6.74 | 21.22% |
| FY2018 | $5.56 | 13.01% |
| FY2017 | $4.92 | 60.26% |
| FY2016 | $3.07 | (0.97%) |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | $1.35 | 55.17% |
| Mar 2026 | $0.87 | (59.72%) |
| Dec 2025 | $2.16 | 120.41% |
| Sep 2025 | $0.98 | (34.23%) |
| 42 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| MTD Mettler-Toledo International, Inc. compare | $44.43 |
| IDXX IDEXX Laboratories, Inc. compare | $14.22 |
| LH Labcorp Holdings Inc. compare | $12.09 |
| DGX Quest Diagnostics Incorporated compare | $9.42 |
| IQV IQVIA Holdings Inc. compare | $8.06 |
| ILMN Illumina, Inc. | $5.36 |
| A Agilent Technologies, Inc. compare | $5.08 |
| WAT Waters Corporation compare | $4.01 |
| NTRA Natera, Inc. compare | −$1.36 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on ILMN
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement